A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

August 1, 2023

Study Completion Date

August 7, 2023

Conditions

Healthy

Interventions

DRUG

Adalimumab

Adalimumab will be administered subcutaneously.

DRUG

Lipopolysaccharide (LPS)

LPS will be administered intravenously.

Trial Locations (1)

Clinical Pharmacology Unit, Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT05884242 - A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge | Biotech Hunter | Biotech Hunter